Reviparin: A review of its efficacy in the prevention and treatment of venous thromboembolism

Drugs

Volumn 61, Issue 8, 2001, Pages 1185-1209

  Wellington, K ^a   McClellan, K ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; PROTAMINE; PROTHROMBIN A; REVIPARIN;

ABDOMINAL SURGERY; BLEEDING; BRACE; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG TOLERABILITY; HEMATOMA; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; NONHUMAN; PHARMACODYNAMICS; POSTOPERATIVE HEMORRHAGE; PREGNANCY; REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

EID: 0034916276     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161080-00017     Document Type: Review

References (56)

1. European consensus statement on the prevention of venous thromboembolism
2. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery
3. Is low-molecular-weight heparin the answer for the therapy of acute deep vein thrombosis?
4. Low-molecular-weight heparin: Prophylaxis and treatment of venous thromboembolism
5. Treatment and prevention of venous thromboembolism
6. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)
7. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial)
8. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study
9. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin
10. Pharmacological profile of reviparin-sodium
11. Low molecular weight heparins: Are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?
12. The release of tissue factor pathway inhibitor (TFPI) in patients receiving prophylactic antithrombotic regimens with unfractioned heparin or LMWH (reviparin)
13. Low molecular weight heparin and haemodialysis: Neutralization by protaminchloride
14. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
15. Low-molecular-weight heparins
16. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers
17. Pharmacokinetics and metabolism of reviparin
18. Heparin/low molecular weight heparin and tissue factor pathway inhibitor
19. Tissue factor pathway inhibitor
20. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers
21. Interaction between the LMWH reviparin and aspirin in healthy volunteers
22. Interaction between GPIIB/IIIA-inhibitors and unfractionated heparin or low molecular weight heparin
23. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients
24. Low molecular weight heparin
25. New data on the pharmacology of heparin and low molecular weight heparins
26. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients: A prospective cohort study
27. Low molecular weight heparin for prevention and treatment of venous thromboembolism in pregnancy
28. Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss
29. Dose finding and pharmacokinetics of prophylactic doses of a low molecular weight heparin (Reviparin TM) in pediatric patients
30. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
31. Efficacy and safety of low molecular weight heparin (Clivarine) in the prophylaxis of venous thromboembolism in patients with brace immobilization after injury of the lower extremity
32. Prevention of venous thromboembolism after knee arthroscopy with low-molecular weight heparin (reviparin): Results of a randomized controlled trial
33. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The COLUMBUS Investigators
34. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
35. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
36. Dose-finding studies of reviparin in elective hip surgery
37. A randomized control trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial
38. Prevention of thromboembolism with low-molecular-weight heparin in operated and non-operated surgical and orthopaedic outpatients
39. Low-molecular-weight heparin for the treatment of deep vein thrombosis
40. Deep venous thrombosis of the lower extremities
41. Thrombolytic therapy for venous thrombosis and pulmonary embolism
42. Low-molecular-weight heparins: Pharmacologic profile and product differentiation
43. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
44. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
45. Low molecular weight heparin in prevention of restenosis after PTCA
46. Risk of and prophylaxis for venous thromboembolism in hospital patients
47. Prevention of deep vein thrombosis after major knee surgery - A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo
48. Thromboprophylaxis with a low molecular weight heparin (Tinzaparin) in emergency abdominal surgery
49. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
50. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin
51. A comparison of subcutaneous low-molecular-heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation